IACS-052584

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NameIACS-052584
Drug Alias Nameallosteric RIPK1 inhibitor (Proteros Biostructures/The University of Texas MD Anderson Cancer Center)IACS-052584
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionReceptor-interacting serine/threonine-protein kinase 1 inhibitors
TargetsReceptor-interacting serine/threonine-protein kinase 1
Therapy Area/IndicationsAlzheimer Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesGermany
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesThe University Of Texas MD Anderson Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesProteros Biostructures GmbHThe University Of Texas MD Anderson Cancer Center
Active IndicationsN/A
Inactive IndicationsAlzheimer Disease

Other Information

ATC CodeN/A
Related LinksN/A